We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Although the days are getting shorter, the GLOW Holiday Festival is returning to CHS Field in Lowertown St. Paul to bring some light to winter’s long, dark nights. Bundle up and make your ...

Oleg Khusaenov examines the challenges and opportunities in Europe’s startup scene, highlighting over €47bn invested in early ...

A paleontologist journeys through Indonesia’s Riau Archipelago in search of our earliest ancestors, and uncovers how ...

Manchester United must repeat the Chido Obi signing this summer with Jesse Derry's Crystal Palace exit now likely.